Adalimumab for cutaneous metastatic Crohn's disease.
Cury
Didia Bismara
DB
Moss
Alan C
AC
Elias
Geraldo
G
Nakao
Alexandre
A
D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011379:Prognosis; D012074:Remission Induction; D012871:Skin Diseases / Q000188:drug therapy* / Q000209:etiology*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab